Tuberculosis in the 90's

Abstract

Get full access to this article

View all access options for this article.

References

Raviglione MC , Snider DE , Kochi A : Global epidemiology of tuberculosis. JAMA 273: 220-226, 1995

WHO. The threat of tuberculosis. 1996

CDC: Tuberculosis Morbidity United States, 1995. MMWR. 45(18):365-370, 1996

CDC: Tuberculosis among foreign-born persons who had recently arrived in the United States Hawaii, 1992-1993, and Los Angeles County, 1993. MMWR 44(38):703-707, 1995

CDC: Characteristics of Foreign-Born Hispanic Patients with Tuberculosis—Eight U.S. Counties Bordering Mexico, 1995. MMWR 45(47):1032-36, 1996

CDC: Estimates of future global tuberculosis morbidity and mortality. MMWR 42:961-964, 1993

CDC: 1993 revised certification system for HIV infection and expanded surveillance case defmition for AIDS among adolescents and adults . MMWR. 41(RR-17):1-19, 1992

Fischl MA , Daikos GL , Uttamchandani RB , et al: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann. Inter. Med. 117:184-89, 1992

CDC: Revision of the CDC surveillance case definitions for acquired immunodeficiency syndrome. MMWR. 36(suppl 1-5):15-155, 1987

10.

American Thoracic Society/Centers for Disease Control. Joint statement: control of tuberculosis in the United States: Am. Rev. Respir. Dis. 146:1623-33, 1992

11.

Brudney K , Dobkin J : Resurgent tuberculosis in New York City. Am. Rev. Respir. Dis. 144: 745-9, 1991

12.

Haas DW and Des Prez RM : Mycobacterium tuberculosis, In Mandell GL , Bennett JE , and Dolin R (eds). Principles and practice of infectious diseases, 4th ed., New York, NY, Churchill Livingston, 1995, pp 2213-43

13.

Peloquin CA , Berning SE : Infection caused by Mycobacterium Tuberculosis . Ann. Pharmacother. 28:72-84, 1994

14.

Daniel TM : Tuberculosis In: Isselbacher KJ , E Braunwald , JD Wilson , et al., eds. Harrison's principles of internal medicine. New York, McGraw-Hill, Inc. pp 710-18, 1994

15.

Shinnick TM , Good RC: Diagnostic mycobacteriology laboratory practices. Clin. Infect. Dis. 21:291-9, 1995

16.

CDC: Management of persons exposed to multidrug-resistant tuberculosis. MMWR 41(RR-11):59-71, 1992

17.

CDC: Meeting the challenge of multidrug-resistant tuberculosis: summary of a conference. MMWR. 41(RR-11):51-57, 1992

18.

Turrett GS , Telzak EE , Torian LV , et al: Improved outcomes for patients with multidrug-resistant tuberculosis . Clin. Infect. Dis. 21:1238-44, 1995

19.

Salomon N , Perlman DC , Friedmann F , Buchstein S , et al: Predictors and outcome of multidrug-resistant tuberculosis. Clin. Infect. Dis. 21:1245-52, 1995

20.

Glassroth J , Houston M : Management of mycobacterial infections. Hosp Formul. 27: 248-60, 1992

21.

Goble M , Iseman MD , Madsen LA , et al.: Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-32, 1993

22.

Koo D , Royce S , Rutherford GW : Drug-resistant mycobacterium tuberculosis in California, 1991-1992. Western J. Med. 163(5): 441-5, 1995

23.

CDC: Initial therapy for tuberculosis in the era of multidrug resistance. MMWR. 42(RR-7): 1-8, 1993

24.

American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. 134: 355-63, 1986

25.

Kopanoff DE , Snider DE, Jr , Caras GJ : Isoniazid-related hepatitis: a U.S. public health service cooperative surveillance study. Am. Rev. Resp. Dis. 117:991-1001, 1978

26.

CDC: The use of preventive therapy for tuberculous infection in the United States: Recommendations of the Advisory Committee for the Elimination of Tuberculosis

MMWR. 39(RR-8):9-12, 1990

27.

Mandell GL and Sande MA : Drugs used in the chemotherapy of tuberculosis and leprosy. In Goodman-Gilman A , Rall TW , Nies AS , Taylor P (eds.), The pharmacological basis of therapeutics, 8th ed. Pergamon Press, New York, New York, 1990 , p. 1146-59

28.

Derby LE , Gutthann SP , Jick H , et al: Liver disorders in patients receiving chlorpromazine or isoniazid . Pharmacotherapy. 13: 353-58, 1993

29.

Bishai WR , Graham NMH, Harrington S , et al: Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N. Engl. J. Med. 334:1573-76, 1996

30.

Grange JM , Winstanley PA , Davies PD : Clinically significant drug interactions with antituberculosis agents. Drug Safety. 11(4):242-51, 1994

31.

Sun E , Heath-Chiozzi M, Cameron DW , et. al: Concurrent ritonavir and rifabutin increase risk of rifabutin-associated adverse event [Abstract no. B.171]. Presented at XI International Conference on AIDS Vancouver, July 8, 1996.

32.

CDC: Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR. 45(42):921-25, 1996

33.

Bartlett JG : Protease inhibitors for HIV infection. Ann. Int. Med. 124;1086-8, 1996

34.

McGregor M , Olliaro P , Wolmarans L , et al: Efficacy and safety of rifabutin in patients with newly-diagnosed pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. (in press)

35.

Schwander S , Rusch-Gerdes S , Mateega A , et al: A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle Lung Dis. 76:210-8, 1995

36.

Blaschke TF and Skinner MH : The clinical pharmacokinetics of rifabutin . Clin. Infect. Dis. 22(suppl 1):S15-S22, 1996

37.

Girling DJ : Adverse effects of antituberculosis drugs. Drugs. 23:56, 1982

38.

Alvarez KL , Krop LC : Ethambutol-induced ocular toxicity revised. Ann. Pharmacother. 27:102-3, 1993

39.

Peloquin CA : Pharmacology of the antimycobacterial drugs. Med. Clin. North Am. 77(6):1253-62, 1993

40.

Rastogi N and Goh KS : In Vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimic. Agents Chemother. 35(9):1933-1936, 1991

41.

Chen CH , Shih JF , Lindholm-levy PJ , Heifets LB : Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis 140:987-989, 1989

42.

Fenlon CH , Cynamon MH: In vitro susceptibility of mycobacteria to ciprofloxacin. J. Antimicrob. Chemother. 16:575-80, 1986

43.

Piersimoni C , Morbiducci V , Bomigia S , DeSio G , et al.: In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis. Am. Rev. of Resp. Dis. 146(6):1445-7, 1992

44.

Sullivan EA , Kreiswirth BN , Palumbo L , et al.: Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet. 345(8958): 1148-50, 1995

45.

Peloquin CA , James GT , McCarthy EA , et al: Pharmacokinetics of ethionamide suppositories. Pharmacotherapy . 11:359, 1991

46.

Peloquin CA , Henshaw TL , Huitt GA , et al.: Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy. 14: 40-46, 1994

47.

Sorg TB and Cynamon M : Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 19:59-64, 1987

48.

Watt B , Edwards J , Rayner A , Grindey A , and Harris G : In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tubercule Lung Dis. 73:134-36, 1992

49.

Zhang Y , Steingrube V , Wallace R : Beta-lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 145:657-60, 1992

50.

Chambers HF , Moreau D , Yajko D , et al.: Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis ? Antimicrob. Agents Chemother. 39(12):2620-24, 1995

51.

Martos A , Podzamczer D , Martinez-Lacasa J , et al.: Steroids do not enhance the risk of developing tuberculosis or other AIDS-related diseases in HIV-infected patients treated for Pneumocystis carinii pneumonia. AIDS. 9:1037-41, 1995

52.

Senderovitz T , Viskum K : Corticosteroids and tuberculosis. Resp. Med. 88:561-65, 1994

53.

Alzeer AH , FitzGerald JM : Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tubercle and Lung Disease. 74:6-11, 1993

54.

Vallejo JG , Ong LT , Starke JR : Clinical features, diagnosis, and treatment of tuberculosis in infants. Pediatrics 94(1):1-7, 1994

55.

Starke JR , Taylor-Watts KT : Tuberculosis in the pediatric population of Houston, Texas. Pediatrics. 84:28-35, 1989

56.

Weis SE , Slocum PC , Flais FX , et al: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. NEJM 330(17):1179-1183, 1994

57.

China Tuberculosis Control Collaboration: Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet. 347:358-62, 1996

58.

Berning SE , Madsen L , Iseman MD , Peloquin CA : Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J. Respir. Crit. Care. Med. 151:2006-9, 1995

59.

Kennedy N , Berger L , Curram J , et al.: Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 22: 827-33, 1996